Case report
A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report
- Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Hematology, Iran University of Medical Science, Tehran, Iran
- Department of Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Correspondence to:
Noorodin Karami,
Department of Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Email:
[email protected].
Published:
2019-05-31
Abstract
Pazopanib is a new tyrosine kinase inhibitor which acts as anti-VEGF signaling and antiangiogenesis. In some countries, this drug has been approved for the treatment of advanced, or metastatic soft tissue sarcoma. Nevertheless, the efficacy of Pazopanib has not yet been proven in patients with advanced liposarcoma. We reported a rare case of advanced liposarcoma that after several courses of chemotherapy, the disease was relapsed, and CT-scan results showed lung metastasis. Therapeutic measures, including surgery and chemotherapy with pazopanib, were successful in destroying the metastatic mass in the patient's lung. Our finding provides a new therapeutic approach for pleomorphic liposarcoma.